Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in Healthy Volunteers Aged 18-60 Years

NCT01863433 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT01863433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01863433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in Healthy Volunteers Aged 18-60 Years
Lead sponsor
Seqirus
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2013
Completion date
June 30, 2013
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human